Arix Bioscience
OverviewSuggest Edit
Arix Bioscience is a provider of venture capital funding services intended to build international group of healthcare and life science businesses. Its services encourage investment in early-stage companies by offering tax benefits in return for the additional risks involved, providing both start-up and later-stage companies with specialized fund management service.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | arixbioscience.com |
Recent NewsAll News
- Arix Bioscience plc: Arix to Present at the Proactive One2One Biotech Forum
- Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States
- Arix Bioscience plc: 2019 Capital Markets Day
- Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
Key People/Management at Arix Bioscience
Naseem Amin
Executive Chairman
Robert Lyne
Chief Operating Officer and General Counsel
Jonathan Tobin
Managing Director
Mark Chin
Investment Director
Noor Lalani
Public Markets Investment Director
Christian Schetter
Managing Director
Arix Bioscience Office Locations
Arix Bioscience has an office in London
London, GB (HQ)
20 Berkeley Square, Mayfair
Arix Bioscience Financials and Metrics
Arix Bioscience Revenue
Arix Bioscience's revenue was reported to be £1.33 m in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 1.3m |
Net income (FY, 2018) | 36.9m |
EBIT (FY, 2018) | 40.8m |
Market capitalization (8-Feb-2021) | 271.2m |
Closing stock price (8-Feb-2021) | 2.0 |
Cash (31-Dec-2018) | 91.2m |
EV | 180.0m |
Arix Bioscience's current market capitalization is £271.2 m.
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Revenue | 1.9m | 1.3m |
Depreciation and amortization | 218.0k | 216.0k |
EBIT | (3.6m) | 40.8m |
EBIT margin, % | (193%) | 3073% |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash | 74.9m | 91.2m |
Accounts Receivable | 275.0k | 1.7m |
Current Assets | 76.2m | 93.4m |
| GBP | FY, 2017 | FY, 2018 |
|---|---|---|
Cash From Operating Activities | (8.8m) | (11.1m) |
Cash From Investing Activities | (50.2m) | (115.4m) |
Cash From Financing Activities | 105.1m | 82.2m |
Net Change in Cash | 46.0m | (44.2m) |
| GBP | FY, 2017 |
|---|---|
Revenue/Employee | 137.6k |
Financial Leverage | 1 x |
Arix Bioscience Cybersecurity Score
Arix Bioscience Online and Social Media Presence
Arix Bioscience's Trends
Arix Bioscience News and Updates
June 09, 2020
Arix Bioscience plc: Arix to Present at the Proactive One2One Biotech Forum
LONDON, June 9, 2020 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that Jonathan Tobin, PhD, Managing Director, will present at the Proactive One2One Virtual...
February 17, 2020
Arix Bioscience plc : Imara Files for Proposed Initial Public Offering in the United States
LONDON, Feb. 17, 2020 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that one of its portfolio companies, Imara Inc., ("Imara"), has filed a...
October 03, 2019
Arix Bioscience plc: 2019 Capital Markets Day
LONDON, Oct. 3, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, is hosting its 2019 Capital Markets Day from 1:45pm today Thursday, 3rd October 2019 in London. The Capital...
September 30, 2019
Arix Bioscience plc: Arix Co-leads EUR 20 Million Series A Investment Round in STipe Therapeutics
LONDON, Sept. 30, 2019 /PRNewswire/ -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has invested in new portfolio company STipe Therapeutics ("STipe"), a company...
September 17, 2019
Arix Bioscience plc: Amplyx Unveils Expanded Pipeline and Reports Phase 2 Data from Lead Programme
LONDON, Sept. 17, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes the following updates from its portfolio company Amplyx Pharmaceuticals ("Amplyx"), a biotech...
September 13, 2019
Arix Bioscience plc - Imara Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering in the United States
LONDON, Sept. 13, 2019 /PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company Imara, Inc. ("Imara"), has confidentially submitted a draft...
Arix Bioscience Blogs
December 03, 2018
Autolus announces update on AUTO4 and AUTO5 programmes
LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced that the first patient has been dosed in its Phase 1/2 LibrA T1 cli…
December 03, 2018
Autolus presents initial AUTO3 clinical data at ASH
LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced updated results from its ongoing AUTO3 Phase 1/2 clinical tria…
November 15, 2018
Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound
LONDON, 15 November 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive…
October 30, 2018
Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011
Multiple doses of AU-011 are well tolerated, with vision preservation observed at 12 to 18 months All Patients met preliminary efficacy endpoint to date with evidence of biological activity Aura plans to initiate a pivotal Phase 3 clinical study LONDON, 30 October 2018: Arix Bioscience plc ("Arix") …
October 11, 2018
Pharmaxis releases positive results of Phase 1 clinical trial for LOXL2 inhibitor compound
LONDON, 11 October 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, tod…
October 10, 2018
Update on LogicBio proposed initial public offering in the United States
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 10 October 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that LogicBio Therapeutics Inc.(“Log…
Arix Bioscience Frequently Asked Questions
When was Arix Bioscience founded?
Arix Bioscience was founded in 2015.
Who are Arix Bioscience key executives?
Arix Bioscience's key executives are Naseem Amin, Robert Lyne and Jonathan Tobin.
How many employees does Arix Bioscience have?
Arix Bioscience has 15 employees.
What is Arix Bioscience revenue?
Latest Arix Bioscience annual revenue is £1.3 m.
What is Arix Bioscience revenue per employee?
Latest Arix Bioscience revenue per employee is £88.5 k.
Who are Arix Bioscience competitors?
Competitors of Arix Bioscience include Tranquis Therapeutics, Juvenescence and Omega Healthcare Investors.
Where is Arix Bioscience headquarters?
Arix Bioscience headquarters is located at 20 Berkeley Square, Mayfair, London.
Where are Arix Bioscience offices?
Arix Bioscience has an office in London.
How many offices does Arix Bioscience have?
Arix Bioscience has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies